Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Single Cell Cytokine Analyses of Bispecific, Tandem, Anti-CD20, Anti-CD19 CAR T-Cells from Patients with Relapsed, Refractory B-Cell Malignancies

Fateeha Furqan, Huiqing Xu, Joanna Zurko, Timothy S. Fenske, Bryon Johnson, Mehdi Hamadani, Nirav N. Shah

Blood (2022) 140 (Supplement 1): 12690–12691.

https://doi.org/10.1182/blood-2022-169198

Published: 2022

Journal Articles

Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Jessica Neumann, Parameswaran Hari, Dina Schneider, Bryon Johnson, Mehdi Hamadani, Timothy S. Fenske

Blood (2022) 140 (Supplement 1): 9318–9319.

https://doi.org/10.1182/blood-2022-158695

Published: 2022

Journal Articles

MRD Status By Clonoseq ® Is a Poor Predictor of Long-Term Outcomes after Bispecific LV20.19 CAR T-Cell Therapy for Relapsed, Refractory B-Cell NHL

Fateeha Furqan, Timothy S. Fenske, Walter L. Longo, Bryon Johnson, Mehdi Hamadani, Nirav N. Shah

Blood (2022) 140 (Supplement 1): 6407–6408.

https://doi.org/10.1182/blood-2022-170047

Published: 2022

Journal Articles

8-Day Versus 12-Day Manufactured LV20.19 CAR T-Cells for B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Jessica Neumann, Walter L. Longo, Parameswaran Hari, Dina Schneider, Bryon Johnson, Timothy S. Fenske, Mehdi Hamadani

Blood (2022) 140 (Supplement 1): 7480–7481.

https://doi.org/10.1182/blood-2022-169119

Published: 2022

Journal Articles

Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, Joanna C. Zurko, Dina Schneider, Sharon Yim, Mehdi Hamadani, Timothy S. Fenske, Bryon Johnson, Parameswaran Hari

Blood (2021) 138 (Supplement 1): 95.

https://doi.org/10.1182/blood-2021-146638

Published: 2021

Journal Articles

A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma

Blood (2021) 138 (Supplement 1): 4401.

https://doi.org/10.1182/blood-2021-149329

Published: 2021

Journal Articles

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Blood (2021) 138 (Supplement 1): 899.

https://doi.org/10.1182/blood-2021-149659

Published: 2021

Journal Articles

Manufacture and Immunological Characterization of GMP-Compliant Functional Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs ® Cytokine Capture System

Blood (2021) 138 (Supplement 1): 476.

https://doi.org/10.1182/blood-2021-145620

Published: 2021

Journal Articles

Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2

Joanna C. Zurko, Huiqing Xu, Katherine Chaney, Timothy S. Fenske, Mehdi Hamadani, Dina Schneider, Parameswaran Hari, Bryon Johnson, Nirav N. Shah

Blood (2021) 138 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2021-146882

Published: 2021

Journal Articles

Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 & IL-15 for a Shorter Duration Improves CAR T-Cell Immunophenotype While Maintaining Target Cell Dose

Joanna C. Zurko, Katherine Chaney, Huiqing Xu, Dina Schneider, Parameswaran Hari, Bryon Johnson, Nirav N. Shah

Blood (2021) 138 (Supplement 1): 3883.

https://doi.org/10.1182/blood-2021-147405

Published: 2021

Journal Articles

Successful Manufacturing of CAR T-Cells with Small Volume Peripheral Blood from Healthy Donors Using the Clinimacs Prodigy Device

Katie Palen, BS, Parameswaran Hari, MD MRCP, Nirav N. Shah, MD, Bryon Johnson, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-136795

Published: 2020

Journal Articles

Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Yaya Chu, PhD, Julie-An Talano, MD, Lee Ann Baxter-Lowe, PhD, Carolyn A. Keever-Taylor, PhD, Erin Morris, RN, BSN, Harshini Mahanti, BS, MSCR, Janet Ayello, MS, MT(ASCP), Bryon Johnson, PhD, Rona Singer Weinberg, PhD, Qiuhu Shi, PhD, Theodore B. Moore, MD, Sandra Fabricatore, RN, PNP, MSN, Brenda J. Grossman, MD, Carmella van de Ven, MA, Shalini Shenoy, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140425

Published: 2020

Journal Articles

Single-Cell RNA Sequencing Identifies Expression Patterns Associated with Clinical Responses to Dual-Targeted CAR-T Cell Therapy

Tyce Kearl, MD PhD, Ao Mei, Ryan Brown, Bryon Johnson, PhD, Dina Schneider, PhD, Boro Dropulic, PhDMBA, Parameswaran Hari, MD MRCP, Nirav N. Shah, MD, Subramaniam Malarkannan, PhD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-142937

Published: 2020

Journal Articles

Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial

Huiqing Xu, MD, Katherine Chaney, MS, Bryon Johnson, PhD, Timothy S. Fenske, MD, Mehdi Hamadani, MD, Boro Dropulic, PhDMBA, Dina Schneider, PhD, Parameswaran Hari, MD MRCP, Nirav N. Shah, MD

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-136805

Published: 2020

Journal Articles

Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-g Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)

Allyson M. Flower, MD, Rachel Friedmann, DO, Janet Ayello, MS, MT(ASCP), Olivia Rigot, PhD, Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Meghan Sturhahn, RN, MSN, Elana Maryamchik, MD, Yongping Wang, MD, Lynn O'Donnell, PhD, Rolla Abu-Arja, MD, Dean Anthony Lee, MD PhD, Julie-An Talano, MD, Bryon Johnson, PhD, Nancy Bunin, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140834

Published: 2020

Journal Articles

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

Nirav N. Shah, MD, Fenlu Zhu, PhD, Dina Schneider, PhD, Winfried Krueger, Andrew Worden, Walter L. Longo, MD, Mehdi Hamadani, MD, Timothy S. Fenske, MD, Boro Dropulic, PhD, Rimas J Orentas, PhD, Parameswaran Hari, MBBS, MD, Bryon Johnson, PhD

Blood (2019) 134 (Supplement_1): 4465.

https://doi.org/10.1182/blood-2019-125328

Published: 2019

Journal Articles

Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL

Fenlu Zhu, PhD, Nirav N Shah, MD, Dina Schneider, PhD, Huiqing Xu, MD, Katherine Chaney, MS, Lawrence Luib, MS, Carolyn A. Keever-Taylor, DPhil, Boro Dropulic, PhD, Rimas Orentas, PhD, Parameswaran Hari, MBBS, MD, Bryon Johnson, PhD

Blood (2018) 132 (Supplement 1): 4553.

https://doi.org/10.1182/blood-2018-99-116566

Published: 2018

Journal Articles

A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

Nirav N Shah, MD, Fenlu Zhu, PhD, Carolyn Taylor, PhD, Dina Schneider, PhD, Winfried Krueger, Andrew Worden, Sharon Yim, Timothy S. Fenske, MD, Mehdi Hamadani, MD, Bryon Johnson, PhD, Boro Dropulic, PhD, Rimas Orentas, PhD, Parameswaran Hari, MBBS, MD

Blood (2018) 132 (Supplement 1): 4193.

https://doi.org/10.1182/blood-2018-99-110194

Published: 2018

Journal Articles

Haploidentical Hematopoietic Cell Transplantation Followed By Donor Natural Killer Cell Infusion and Sirolimus Maintenance Can Successfully Treat Patients with High-Risk Ewing Sarcoma

Monica Thakar, MD, Meghen Browning, MD, Parameswaran Hari, MD MRCP, MS, John Charlson, MD, Amy Newman, PhD, Brent R. Logan, PhD, Nathan Schloemer, MD, Michael Kelly, MD PhD, Bryon Johnson, PhD, Subramaniam Malarkannan, PhD, Carolyn A. Keever-Taylor, DPhil

Blood (2017) 130 (Supplement 1): 4525.

https://doi.org/10.1182/blood.V130.Suppl_1.4525.4525

Published: 2017

Journal Articles

Phase 2 Study of Pembrolizumab during Lymphodepleted State after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients

Attaphol Pawarode, MD, Anita D'Souza, MBBS, Marcelo C. Pasquini, MD, Bryon Johnson, PhD, Thomas Braun, PhD, Binod Dhakal, MBBS, Mehdi Hamadani, MD, John M. Magenau, MD, Nirav N Shah, MD, Mary Mansour Riwes, DO, Brian Parkin, MD, Pavan Reddy, MD, Parameswaran Hari, MD MRCP, MS

Blood (2017) 130 (Supplement 1): 339.

https://doi.org/10.1182/blood.V130.Suppl_1.339.339

Published: 2017

NARROW

Single Cell Cytokine Analyses of Bispecific, Tandem, Anti-CD20, Anti-CD19 CAR T-Cells from Patients with Relapsed, Refractory B-Cell Malignancies

Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma

MRD Status By Clonoseq ® Is a Poor Predictor of Long-Term Outcomes after Bispecific LV20.19 CAR T-Cell Therapy for Relapsed, Refractory B-Cell NHL

8-Day Versus 12-Day Manufactured LV20.19 CAR T-Cells for B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma

A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Manufacture and Immunological Characterization of GMP-Compliant Functional Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs ® Cytokine Capture System

Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2

Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 & IL-15 for a Shorter Duration Improves CAR T-Cell Immunophenotype While Maintaining Target Cell Dose

Successful Manufacturing of CAR T-Cells with Small Volume Peripheral Blood from Healthy Donors Using the Clinimacs Prodigy Device

Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Single-Cell RNA Sequencing Identifies Expression Patterns Associated with Clinical Responses to Dual-Targeted CAR-T Cell Therapy

Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial

Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma

Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL

A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

Haploidentical Hematopoietic Cell Transplantation Followed By Donor Natural Killer Cell Infusion and Sirolimus Maintenance Can Successfully Treat Patients with High-Risk Ewing Sarcoma

Phase 2 Study of Pembrolizumab during Lymphodepleted State after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only